Uromigos Live 2023 - Bladder RT

Advertisement
Thomas Powles, MBBS, MRCP, MDRoundtable | November 30, 2023
The panel shares predictions for the future of bladder cancer.
View More
Thomas Powles, MBBS, MRCP, MDRoundtable | November 30, 2023
The panel discusses other exciting treatment advances in bladder cancer.
Thomas Powles, MBBS, MRCP, MDRoundtable | November 30, 2023
How the potential shift of new therapies to the frontline setting will impact subsequent treatment decisions.
Thomas Powles, MBBS, MRCP, MDRoundtable | November 30, 2023
The panel discussed optimal treatment cycles for enfortumab vedotin/pembrolizumab.
Thomas Powles, MBBS, MRCP, MDRoundtable | November 30, 2023
The panel shared their thoughts on the EV-302 study.
Thomas Powles, MBBS, MRCP, MDRoundtable | November 30, 2023
The panel kicked off with conversations about data released at ESMO, including EV-302 and CheckMate 901.
Peter O'Donnell, MDRoundtable | November 17, 2023
The panel shares their hopes for the future of bladder cancer treatment.
Peter O'Donnell, MDRoundtable | November 17, 2023
The panel shares tips for community oncologists who may not be familiar with treating patients with EV/pembro.
Peter O'Donnell, MDRoundtable | November 17, 2023
The panel shares treatment sequencing decisions based on a few patient scenarios.
Peter O'Donnell, MDRoundtable | November 17, 2023
The panel discussed the double antibody-drug conjugate trial that assessed sacituzumab govitecan plus EV.
Peter O'Donnell, MDRoundtable | November 17, 2023
The panel shares lessons learned from the phase THOR study.
Peter O'Donnell, MDRoundtable | November 17, 2023
The panel discusses the CheckMate 901 study results.
Peter O'Donnell, MDRoundtable | November 17, 2023
The panel discussed how the EV-302 data compare to the previous JAVELIN paradigm.
Peter O'Donnell, MDRoundtable | November 17, 2023
The panel discusses the "buzz" around the EV-302 study.
Peter O'Donnell, MDRoundtable | November 17, 2023
The panel discussed continued unmet needs and challenges for patients with urothelial cancer.
Advertisement
Advertisement
Advertisement